Regenxbio (RGNX)

• Market cap: $298M
• 1 day: 3.72%
• 5 days: 50.82%
• 1 month: 5.75%
• 3 months: 16.75%
• 6 months: -3.97%
• Year to date: 17.05%
• 1 year: -42.64%
• 5 years: -77.79%
• 10 years: -69.79%
• Sector: Healthcare
• Industry: Biotechnology

About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Employees: 353

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

183% more call options, than puts

Call options by funds: $1.4M | Put options by funds: $494K

16% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 50

3.4% less ownership

Funds ownership: 88.36% [Q3] → 84.96% (-3.4%) [Q4]

5% less funds holding

Funds holding: 186 [Q3] → 177 (-9) [Q4]

11% less first-time investments, than exits

New positions opened: 39 | Existing positions closed: 44

29% less capital invested

Capital invested by funds: $458M [Q3] → $325M (-$133M) [Q4]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q3] → 2 (-1) [Q4]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $12 30% upside
• Avg. target: $31 239% upside
• High target: $52 465% upside

5 analyst ratings

• positive: 4 80%
• neutral: 1 20%
• negative: 0 0%

Goldman Sachs Paul Choi 67% 1-year accuracy 10 / 15 met price target	30% upside $12	Neutral Maintained	17 Apr 2025
HC Wainwright & Co. Yi Chen 28% 1-year accuracy 47 / 170 met price target	270% upside $34	Buy Reiterated	21 Mar 2025
Chardan Capital Daniil Gataulin 14% 1-year accuracy 7 / 50 met price target	465% upside $52	Buy Maintained	20 Mar 2025
HC Wainwright & Co. Raghuram Selvaraju 32% 1-year accuracy 105 / 330 met price target	270% upside $34	Buy Maintained	17 Mar 2025
Morgan Stanley Judah Frommer 50% 1-year accuracy 5 / 10 met price target	161% upside $24	Overweight Maintained	14 Mar 2025